Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata

The document reports a case where an 80-year-old female patient with ulcerative colitis (UC), pyoderma gangrenosum (PG), and alopecia areata (AA) experienced improvement in all three conditions after being treated with tofacitinib, a pan-janus kinase (JAK) inhibitor. The patient had previously been treated with oral aminosalicylates, systemic and intralesional corticosteroids, topical tacrolimus, adalimumab, and methotrexate, with only partial response or nonresponse. In July 2020, she was prescribed 11 mg/day of tofacitinib XL, which led to clinical remission of UC by September 2020, as well as marked improvement in both AA and PG, without any adverse events. This case highlights the potential of tofacitinib to simultaneously treat multiple autoimmune conditions in patients who have not responded to other systemic biological and immunosuppressive medications.